title: Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?
authors.forename: Thierry
authors.initials: T
authors.lastname: Poynard
authors.forename: Dominique
authors.initials: D
authors.lastname: Thabut
authors.forename: Ariane
authors.initials: A
authors.lastname: Chryssostalis
authors.forename: Julien
authors.initials: J
authors.lastname: Taieb
authors.forename: Vlad
authors.initials: V
authors.lastname: Ratziu
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006519:Hepatitis, Alcoholic / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab